Tag Archives: BRAF V600E

May, 2018

December, 2017

  • 22 December

    Novartis’ Combo Therapy for Melanoma Receives FDA Priority Review

    EAST HANOVER, N.J., Dec. 22, 2017 /PRNewswire/ — Novartis announced today the US Food and Drug Administration (FDA) has accepted the Company’s supplemental New Drug Application (sNDA) for filing, and granted Priority Review designation for Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage …

October, 2017

June, 2017

November, 2015

  • 23 November

    Roche’s Melanoma Drug Performs Well in Early-Stage Study

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the pivotal coBRIM study, which showed that Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib) helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live significantly longer (overall survival; OS) than with Zelboraf alone.1 Cotellic plus Zelboraf reduced …